DE69406440D1 - Arzneimittelzusammensetzung für verabreichung von nikotin durch die nase - Google Patents

Arzneimittelzusammensetzung für verabreichung von nikotin durch die nase

Info

Publication number
DE69406440D1
DE69406440D1 DE69406440T DE69406440T DE69406440D1 DE 69406440 D1 DE69406440 D1 DE 69406440D1 DE 69406440 T DE69406440 T DE 69406440T DE 69406440 T DE69406440 T DE 69406440T DE 69406440 D1 DE69406440 D1 DE 69406440D1
Authority
DE
Germany
Prior art keywords
nicotine
ion
pct
exchange
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69406440T
Other languages
English (en)
Other versions
DE69406440T2 (de
Inventor
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Publication of DE69406440D1 publication Critical patent/DE69406440D1/de
Application granted granted Critical
Publication of DE69406440T2 publication Critical patent/DE69406440T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69406440T 1993-05-20 1994-05-20 Arzneimittelzusammensetzung für verabreichung von nikotin durch die nase Expired - Fee Related DE69406440T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939310412A GB9310412D0 (en) 1993-05-20 1993-05-20 Nasal nicotine system
PCT/GB1994/001092 WO1994027576A1 (en) 1993-05-20 1994-05-20 Nasal drug delivery composition containing nicotine

Publications (2)

Publication Number Publication Date
DE69406440D1 true DE69406440D1 (de) 1997-11-27
DE69406440T2 DE69406440T2 (de) 1998-04-02

Family

ID=10735826

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69406440T Expired - Fee Related DE69406440T2 (de) 1993-05-20 1994-05-20 Arzneimittelzusammensetzung für verabreichung von nikotin durch die nase

Country Status (14)

Country Link
US (1) US5935604A (de)
EP (1) EP0697858B1 (de)
JP (1) JPH08510467A (de)
AT (1) ATE159425T1 (de)
AU (1) AU685458B2 (de)
CA (1) CA2163089A1 (de)
DE (1) DE69406440T2 (de)
DK (1) DK0697858T3 (de)
ES (1) ES2111304T3 (de)
FI (1) FI955583A (de)
GB (2) GB9310412D0 (de)
GR (1) GR3025890T3 (de)
NO (1) NO306847B1 (de)
WO (1) WO1994027576A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303574D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
EP0898961A1 (de) * 1997-08-27 1999-03-03 Herta-Maria Dr. Sahlender Pharmazeutische Zubereitung zur verbesserten Schmerztherapie bei akutem, postoperativem oder chronischem Schmerz
EP1035833B1 (de) * 1997-12-02 2005-08-31 Archimedes Development Limited Zusammensetzungen zur nasalen verabreichung
FR2771929B1 (fr) * 1997-12-09 2001-02-23 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US20020098264A1 (en) * 1998-11-27 2002-07-25 Cherukuri Subraman R. Medicated chewing gum delivery system for nicotine
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
CA2346656A1 (en) * 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
ES2350306T3 (es) * 1999-02-26 2011-01-20 Novartis Vaccines And Diagnostics, Inc. Uso de bioadhesivos y adyuvantes para la administración de antígenos por vía mucosa.
US6799576B2 (en) * 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
WO2001005459A1 (en) * 1999-07-16 2001-01-25 Aradigm Corporation System for effecting smoke cessation
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US8256433B2 (en) * 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US20080138398A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US20080138294A1 (en) * 1999-07-16 2008-06-12 Igor Gonda Systems and methods for effecting cessation of tobacco use
AT409219B (de) * 1999-08-13 2002-06-25 Red Bull Gmbh Verwendung von nikotin zum herstellen von arzneimitteln
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
EP1383376A4 (de) * 2001-03-19 2006-03-08 Praecis Pharm Inc Pharmazeutische formulierungen für die anhaltende wirkstofffreigabe
AR033444A1 (es) * 2001-03-26 2003-12-17 Smithkline Beecham Corp Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20040101543A1 (en) * 2002-03-22 2004-05-27 John Liu Nicotine-containing oral dosage form
US6586449B1 (en) * 2002-05-28 2003-07-01 Cambrex Charles City, Inc. Nicotine-containing, controlled release composition and method
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
DK1803444T3 (en) 2002-12-20 2019-02-25 Niconovum Ab PROCEDURE FOR PREPARING A NICOTIC PARTICULATE MATERIAL WITH A CRYSTALLINE CELLULOSE (ESPECIALLY MCC)
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
CN100575955C (zh) * 2003-04-30 2009-12-30 纳斯泰克制药公司 密蛋白的未表达作为肿瘤转移的标记物
WO2004104490A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
WO2005007074A2 (en) * 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
AU2004283431B2 (en) * 2003-10-10 2009-09-10 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
WO2005053691A2 (en) 2003-12-02 2005-06-16 Fertin Pharma A/S Nicotine delivery product and method for producing it
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
CN105853394A (zh) * 2006-03-30 2016-08-17 恩根尼公司 用于体内转染肠细胞的非病毒组合物和方法
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
EP2086317A4 (de) * 2006-12-01 2010-03-03 Aradigm Corp Nikotinformulierungen, kits und systeme und verfahren zu ihrer verwendung
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
EP2121088B1 (de) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Erhitzungseinheit zur verwendung in einer arzneimittelabgabevorrichtung
US20080287507A1 (en) * 2007-05-16 2008-11-20 John Hedenstrom Nicotine containing toiletry waters
JP2009209086A (ja) * 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
EP2392331A1 (de) * 2008-12-19 2011-12-07 Siegfried Ltd. Nikotinhaltiges Produkt
WO2011049960A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Compositions and methods for the treatment of sinonasal disorders
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
US10130120B2 (en) 2013-03-15 2018-11-20 Altria Client Services Llc Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
US10792301B2 (en) * 2015-02-13 2020-10-06 The University Of Toledo Therapeutic polysaccharide midi-GAGR and related materials and methods
WO2017151651A1 (en) * 2016-02-29 2017-09-08 Belmont University Pharmaceutical in situ gelling compositions
MX2018012439A (es) 2016-04-12 2019-02-21 Solis Herrera Arturo Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico.
WO2018113916A1 (en) * 2016-12-20 2018-06-28 Fertin Pharma A/S A mucoadhesive oromucosal formulation comprising a nicotine complex
CN111447921B (zh) * 2017-12-08 2023-10-13 费尔廷制药公司 烟碱片剂
WO2022132018A1 (en) * 2020-12-16 2022-06-23 Liw Innovation Ab A new powder composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945783A (en) * 1957-06-20 1960-07-19 Reheis Company Inc Aluminum protein antacid and process of making
US3655866A (en) * 1970-01-26 1972-04-11 Warner Lambert Co Sugarless gum containing dicalcium phosphate dihydrate
CA1139221A (en) * 1978-10-10 1983-01-11 Vijay B. Surpuriya Antacid compositions
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
GB2133691B (en) * 1983-01-21 1986-05-21 Leo Ab Smoking substitutes for nasal administration
US4655231A (en) * 1984-01-09 1987-04-07 Advanced Tobacco Products, Inc. Snuff and preparation thereof
IL73912A0 (en) * 1984-01-09 1985-03-31 Advanced Tobacco Prod Nicotine preparation
AU582167B2 (en) * 1984-06-28 1989-03-16 Procter & Gamble Company, The Antacid composition
US4971787A (en) * 1984-08-27 1990-11-20 Warner-Lambert Company Antacid chewing gum
US4882152A (en) * 1985-12-20 1989-11-21 Yang Robert K Confectionery delivery system for laxatives, vitamins and antacids
DK179687D0 (da) * 1987-04-08 1987-04-08 Farma Food As Praeparat
GB8809421D0 (en) * 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
US5525351A (en) * 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
SE8904295D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Smoking substitute
DE4140116A1 (de) * 1991-12-05 1993-06-09 Bolder Arzneimittel Gmbh Dimeticon-pastillen
GB9200047D0 (en) * 1992-01-03 1992-02-26 Univ Alberta Nicotine-containing nasal spray
JPH09501678A (ja) * 1993-08-13 1997-02-18 ベイヤー、コーポレーション かむ錠剤の芳香増進剤としての加水分解ゼラチン
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
WO1996000072A1 (en) * 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine

Also Published As

Publication number Publication date
ATE159425T1 (de) 1997-11-15
NO954582L (no) 1995-11-14
GB9310412D0 (en) 1993-07-07
DK0697858T3 (da) 1998-05-04
EP0697858A1 (de) 1996-02-28
ES2111304T3 (es) 1998-03-01
JPH08510467A (ja) 1996-11-05
NO954582D0 (no) 1995-11-14
DE69406440T2 (de) 1998-04-02
EP0697858B1 (de) 1997-10-22
AU6727294A (en) 1994-12-20
US5935604A (en) 1999-08-10
CA2163089A1 (en) 1994-12-08
FI955583A (fi) 1996-01-19
GB9523372D0 (en) 1996-01-17
AU685458B2 (en) 1998-01-22
GR3025890T3 (en) 1998-04-30
WO1994027576A1 (en) 1994-12-08
FI955583A0 (fi) 1995-11-20
GB2292316B (en) 1997-03-26
NO306847B1 (no) 2000-01-03
GB2292316A (en) 1996-02-21

Similar Documents

Publication Publication Date Title
DE69406440T2 (de) Arzneimittelzusammensetzung für verabreichung von nikotin durch die nase
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
GR3033301T3 (en) Medicament form for the delivery of active substances to wounds
ATE195249T1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
MY131730A (en) Medicated tissue paper product
HUP0000520A2 (hu) Új vizes gyógyszerkészítmények hajtógázmentes aeroszolokhoz
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
FI941771A (fi) Tehostettu ihonläpäisyjärjestelmä lääkeaineiden parannettua paikallista antoa varten
ATE297204T1 (de) Heilmittel für neurodegenerative krankheiten
ES2099428T3 (es) Composiciones farmaceuticas para inhalacion.
NO951996L (no) Leveringsinnretning med innkapslede eksipienser
NO952906D0 (no) Farmasöytisk formulering for behandling av nikotinavhengighet
WO2003009829A3 (en) Antiemetic, anti-motion sustained release drug delivery system
DK0615441T3 (da) Ibuprofenholdigt lægemiddel til akut brug og dets anvendelse
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
DK0615443T3 (da) Lægemiddel i akut virksom form indeholdende Flurbiprofen og anvendelse deraf
IT1254707B (it) Uso topico della calcitonima per la preparazione di medicamenti nella cataratta idiopatica senile e una composizione farmaceutica che la contiene
TH51486A (th) สูตรตำรับใหม่ของเมอร์ทาซาพีน

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINI

8339 Ceased/non-payment of the annual fee